Overall, we have shown that STs, and in particular ST3GAL4 and ST3GAL3 that lead to the sLex/a biosynthesis can be considered as potential therapeutic targets against pancreatic cancer. This evidence concerns the gene ST3GAL4 and pancreatic neoplasm.